A unique cell surface antigen identifying lymphoid malignancies of B cell origin

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Leukemias and lymphomas are cancers of blood and lymphoid tissues, respectively.
• Accurate classification of these malignancies is crucial for effective treatment.
• B cell surface antigens are key markers for identifying and categorizing B cell-derived tumors.

Purpose of the Study:

• To characterize malignant cells in leukemias and lymphomas using a specific B cell surface antigen marker.
• To determine the expression of the B1 antigen on various types of leukemia and lymphoma.
• To investigate the potential shared B cell lineage of different lymphoid malignancies.

Main Methods:

• Utilized a monoclonal antibody (anti-B1) that targets a unique B cell surface differentiation antigen.
• Applied immunophenotyping to analyze malignant cells from patients with different leukemias and lymphomas.
• Correlated B1 antigen expression with other known markers such as kappa/lambda light chains and common acute lymphoblastic leukemia antigen (CALLA).

Main Results:

• All lymphomas and chronic lymphocytic leukemias (CLL) expressed the B1 antigen.
• T cell leukemias/lymphomas and acute myeloblastic leukemia were negative for B1.
• Approximately 50% of non-T acute lymphoblastic leukemias (ALL) and 75% of common ALL antigen (CALLA)-positive ALL expressed B1, while CALLA-negative ALL did not.

Conclusions:

• The B1 antigen is a reliable marker for identifying B cell lineage in lymphoid malignancies.
• The majority of B cell lymphomas and a significant proportion of CALLA-positive ALL share B1 expression, suggesting a common B cell origin.
• These findings support the utility of B1 antigen in the classification and understanding of B cell-derived leukemias and lymphomas.